{"id":3739,"date":"2023-07-21T09:57:55","date_gmt":"2023-07-21T16:57:55","guid":{"rendered":"https:\/\/grail.com\/?page_id=3739"},"modified":"2025-09-25T14:45:59","modified_gmt":"2025-09-25T21:45:59","slug":"biopharma-partnerships","status":"publish","type":"page","link":"https:\/\/grail.com\/biopharma-partnerships\/","title":{"rendered":"Biopharma Partnerships"},"content":{"rendered":"\n\n
\n
\n
\n
\n
\n \"grail\n <\/div>\n
\n \"Background\n <\/div>\n
\n \"Background\n <\/div>\n <\/div>\n
\n \"\"\n

Biopharma Partnerships<\/h2>\n
\n

Advancing novel cancer therapeutics through next generation liquid biopsy solutions.<\/p>\n

Our Pharma Partnership Makes It Possible\u00a0<\/strong>
\nWe help our pharma partners accelerate precision oncology across cancer indications and therapeutic modalities with research to clinical trials and ultimately, registration and commercial launch.<\/p>\n

Our team brings together biopharma and companion diagnostics expertise with biomarker, drug-diagnostic co-development, and commercialization experience.<\/p>\n

Our pharma partnerships deliver cancer detection, classification, and quantification results with the potential to analyze and monitor epigenetic signatures from early to advanced stage cancer.<\/p>\n

Data from GRAIL studies have demonstrated analytically validated performance1<\/sup> with robust analytical sensitivity, specificity, and precision.<\/p>\n

We leverage the combination of GRAIL\u2019s proprietary methylation-based multi-cancer early detection (MCED) liquid biopsy platform and biologically motivated machine learning capabilities.<\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n\n\n\n

<\/div>\n\n\n\n

GRAIL Cancer Research Solution : a multi-cancer ctDNA toolkit for biopharma research and clinical testing<\/h2>\n\n\n\n

GRAIL’s Cancer Research Solution is a blood-only ctDNA platform for sensitive and specific cancer detection, with the aim to advance precision cancer care. With one tube of blood, the test analyzes more than a million CpGs identified through population-scale clinical studies2,3<\/sup> and leverages machine learning classifiers to detect, classify, and quantify ctDNA4<\/sup>. <\/p>\n\n\n\n

GRAIL’s Tissue-free Platform to Support Precision Cancer Care<\/h4>\n\n\n\n
\"\"\n\t\t\t\n\t\t\t\t\n\t\t\t<\/svg>\n\t\t<\/button><\/figure>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n\n\n\n

Potential Applications Across the Cancer Care Continuum<\/h4>\n\n\n\n
\"\"\n\t\t\t\n\t\t\t\t\n\t\t\t<\/svg>\n\t\t<\/button><\/figure>\n\n\n\n

<\/p>\n\n\n\n

This enables ctDNA applications spanning from exploratory research and biomarker studies to clinical trial stratification and selection. GRAIL\u2019s Cancer Research Solution and tunable machine learning architecture are poised to support novel biopharma precision oncology strategies.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Applications and Key Publications<\/h2>\n\n\n\n
\n
\n
\n